Filing Flows › Comparisons › FHTX vs ENTA
Foghorn Therapeutics vs Enanta Pharmaceuticals: FHTX and ENTA compared
Foghorn Therapeutics is the larger company: $16.1M of revenue in its latest quarter (Q2 2026) against $14.4M for Enanta Pharmaceuticals (Q3 FY26). Foghorn Therapeutics is growing faster (+113% against -22% a year earlier). Foghorn Therapeutics is more profitable, with an operating margin of -54.8% against -120.0%.
Where the money goes: FHTX and ENTA
Foghorn Therapeutics (FHTX) · Q2 2026
Foghorn Therapeutics, Q2 2026: revenue $16.1M (+113% year over year), operating margin -54.8%, net loss $7.2M, operating cash flow −$17.8M. The chart follows the revenue to costs, profit and cash.
Enanta Pharmaceuticals (ENTA) · Q3 FY26
Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%, net loss $19.5M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
| Foghorn Therapeutics (FHTX) | Enanta Pharmaceuticals (ENTA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 FY26 |
| Revenue | $16.1M | $14.4M |
| Revenue growth, Y/Y | +113% | -22% |
| Operating margin | -54.8% | -120.0% |
| Net earnings | −$7.2M | −$19.5M |
| Net margin | -44.7% | -135.8% |
| Operating cash flow | −$17.8M | −$10.0M |
| Market value | $132M | — |
| Analysts’ mean target | $4.17 | — |
Questions
Which is bigger, Foghorn Therapeutics or Enanta Pharmaceuticals?
Foghorn Therapeutics is the larger company: $16.1M of revenue in its latest quarter (Q2 2026) against $14.4M for Enanta Pharmaceuticals (Q3 FY26).
Is Foghorn Therapeutics or Enanta Pharmaceuticals growing faster?
Foghorn Therapeutics is growing faster (+113% against -22% a year earlier).
Which is more profitable, Foghorn Therapeutics or Enanta Pharmaceuticals?
Foghorn Therapeutics is more profitable, with an operating margin of -54.8% against -120.0%.
More: Foghorn Therapeutics earnings · how Foghorn Therapeutics makes money · Enanta Pharmaceuticals earnings · how Enanta Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.